West Pharmaceutical Services Inc. (NYSE:WST) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 668,400 shares, a growth of 12.2% from the September 30th total of 595,700 shares. Based on an average daily volume of 343,700 shares, the short-interest ratio is presently 1.9 days. Approximately 0.9% of the company’s stock are short sold.
Several institutional investors have recently added to or reduced their stakes in the company. First Allied Advisory Services Inc. grew its position in shares of West Pharmaceutical Services by 5.3% during the 3rd quarter. First Allied Advisory Services Inc. now owns 3,327 shares of the medical instruments supplier’s stock valued at $474,000 after acquiring an additional 168 shares during the period. Trillium Asset Management LLC boosted its holdings in West Pharmaceutical Services by 17.0% in the 3rd quarter. Trillium Asset Management LLC now owns 25,893 shares of the medical instruments supplier’s stock worth $3,672,000 after buying an additional 3,762 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its holdings in West Pharmaceutical Services by 0.3% in the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 21,028 shares of the medical instruments supplier’s stock worth $2,982,000 after buying an additional 70 shares during the period. Great Lakes Advisors LLC boosted its holdings in West Pharmaceutical Services by 3.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 84,046 shares of the medical instruments supplier’s stock worth $11,920,000 after buying an additional 2,960 shares during the period. Finally, Eqis Capital Management Inc. bought a new position in West Pharmaceutical Services in the 3rd quarter worth approximately $267,000. 89.56% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts have issued reports on the stock. ValuEngine downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $160.00 price objective for the company in a research report on Sunday, November 3rd. Finally, Bank of America raised shares of West Pharmaceutical Services from an “underperform” rating to a “neutral” rating in a research report on Friday, July 26th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $131.39.
West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 24th. The medical instruments supplier reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.08. West Pharmaceutical Services had a net margin of 12.82% and a return on equity of 16.66%. The firm had revenue of $456.10 million during the quarter, compared to the consensus estimate of $450.03 million. During the same period in the prior year, the firm earned $0.76 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. As a group, analysts anticipate that West Pharmaceutical Services will post 3.14 earnings per share for the current year.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
See Also: How liquidity affects the bid-ask spread
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.